Final NICE ‘No’ for Pfizer’s Xalkori

The UK’s NICE has decided that patients with advanced non-small-cell lung cancer will not have access to Pfizer’s Xalkori through the National Health Service, claiming the drug does not provide enough value for money.
Pharma Times